Halothane-induced liver injury in guinea-pigs: Importance of cytochrome P450 enzyme activity and hepatic blood flow

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 6, 1996, Pages 594-601

  Farrell, Geoffrey C ^a,b   Frost, Linda ^a   Tapner, Michael ^a   Field, Jacqueline ^a   Weltman, Martin ^a   Mahoney, Janette ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

CYP2E1; Cytochrome P450 enzymes; Drug metabolism; Genetic susceptibility; Halothane; Hepatic blood flow; Liver injury

Indexed keywords

CYTOCHROME P450; HALOTHANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; GENETIC SUSCEPTIBILITY; GUINEA PIG; INHALATIONAL DRUG ADMINISTRATION; LIVER BLOOD FLOW; LIVER INJURY; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029903096     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb01708.x     Document Type: Article

References (49)

1. Brown BR, Sipes GI. Biotransformation and hepatotoxicity of halothane. Biochem. Pharmacol. 1977; 26: 2091-4.
2. Touloukian J, Kaplowitz N. Halothane-induced hepatic disease. Semin. Liver Dis. 1981; 1: 134-42.
3. Gelman S. Halothane hepatotoxicity-again? Anesth. Analg. 1986; 65: 831-4.
4. Neuberger J, Kenna JG. Halothane hepatitis: A model of immune mediated drug hepatotoxicity. Clin. Sci. 1987; 72: 263-70.
5. Farrell GC. Mechanism of halothane-induced liver injury: Is it immune or metabolic idiosyncrasy? J. Gastroenterol. Hepatol. 1988; 3: 465-82.
6. Farrell GC. Liver disease due to anaesthetic agents. In: Farrell GC, ed. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994; 389-412.
7. 14C]halothane. J. Pharmacol. Exp. Ther. 1980; 214: 721-5.
8. Trudell JR, Bösterling B, Trevor AJ. Reductive metabolism of halothane by human and rabbit cytochrome P-450. Binding of 1-chloro-2,2,2-trifluorethyl radical to phospholipids. Mol. Pharmacol. 1982; 21: 710-17.
9. Van Dyke RA, Baker MT, Jansson I, Schenkman J. Reductive metabolism of halothane by purified cytochrome P-450. Biochem. Pharmacol. 1988; 37: 2357-61.
10. Greunke LD, Konopka K, Koop DR, Waskell LA. Characterization of halothane oxidation by hepatic microsomes and purified cytochrome P450 using a gas chromatographic mass spectrometric assay. J. Pharmacol. Exp. Ther. 1988; 246: 454-9.
11. Raucy JL, Kraner JC, Lasker JM. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit. Rev. Toxicol. 1993; 23: 1-20.
12. Bentley JB, Vaughan RW, Gandolfi J, Gork RC. Halothane biotransformation in obese and nonobese patients. Anesthesiology 1982; 57: 94-7.
13. Farrell G, Prendergast D, Murray M. Halothane hepatitis. Detection of a constitutional susceptibility factor. N. Engl. J. Med. 1985; 313: 1310-14.
14. Mieli-Vergani G, Vergani D, Tredger JM, Eddleston ALWF, Davis M, Williams R. Lymphocyte cytotoxicity to halothane altered hepatocytes in patients with severe hepatic necrosis following halothane anaesthesia. J. Clin. Lab. Immunol. 1980; 4: 49-51.
15. Smith GCM, Kenna JG, Harrison DJ, Tew D, Wolf CR. Autoantibodies to hepatic microsomal carboxylesterase in halothane hepatitis. Lancer 1993; 342: 963-4.
16. Satoh H, Gillette JR, Davis HW, Schulick RD, Pohl LR. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol. Pharmacol. 1985; 28: 468-74.
17. Satoh H, Martin BM, Schulick AH, Christ DD, Kenna JG, Pohl LR. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc. Natl Acad. Sci. USA 1989; 86: 322-6.
18. Kenna JG, Knight TL, Van Pelt FNAM. Immunity of halothane metabolite-modified proteins in halothane hepatitis. Ann. N.Y. Acad. Sci. 1993; 685: 646-61.
19. Martin JL, Kenna JG, Martin BM, Thomassen D, Reed GF, Pohl LR. Halothane hepatitis patients with serum antibodies that react with protein disulfide isomerase. Hepatology 1993; 18: 858-63.
20. Cousins MJ, Sharp JH, Gourlay GK, Adams JF, Haynes WD, Whitehead R. Hepatotoxicity and halothane metabolism in an animal model with application for human toxicity. Anaesth. Intens. Care 1979; 7: 9-24.
21. McLain GE, Sipes IG, Brown BR Jr. An animal model of halothane hepatotoxicity: Roles of enzyme induction and hypoxia. Anesthesiology 1979; 51: 321-6.
22. Takagi T, Ishii H, Takahashi H et al. Potentiation of halothane hepatotoxicity by chronic ethanol administration in rat: An animal model of halothane hepatitis. Pharmacol. Biochem. Behav. 1983; 18 (Suppl. 1): 461-5.
23. Rice SA, Maze M, Smith CM, Kosek JC, Mazze RI. Halothane hepatotoxicity in Fischer 344 rats pretreated with isoniazid. Toxicol. Appl. Pharmacol 1987; 87: 411-19.
24. Lunam CA, Cousins MJ, Hall P De La M. Guinea-pig model of halothane-associated hepatotoxicity in the absence of enzyme induction and hypoxia. J. Pharmacol. Exp. Ther. 1985; 232: 802-9.
25. Lunam CA, Cousins MJ, Hall P de la M. Genetic predisposition to liver damage after halothane anesthesia in guinea pigs. Anesth. Analg. 1986; 65: 1143-8.
26. Lind RF, Gandolfi AJ, Brown BR Jr, Hall P de la M. Halothane hepatotoxicity in guinea pigs. Anesth. Analg. 1987; 66: 222-8.
27. Und RC, Gandolfi AJ, Hall P de la M. The role of oxidative biotransformation of halothane in the guinea pig model of halothane-associated hepatotoxicity. Anesthesiology 1989; 70: 649-53.
28. Farrell GC, Mahoney J, Bilous M, Frost L. Altered hepatic calcium homeostasis in guinea pigs with halothane-induced hepatotoxicity. J. Pharmacol. Exp. Ther. 1988; 247: 751-6.
29. Akita S, Morio M, Kawahara M, Takeshita T, Fujii K, Yamamoto M. Halothane-induced liver injury as a consequence of enhanced microsomal lipid peroxidation in guinea pigs. Res. Commun. Chem. Pathol. Pharmacol. 1988; 61: 227-43.
30. Hoft RH, Bunker JP, Goodman HI, Gregory PB. Halothane hepatitis in three pairs of closely related women. N. Engl. J. Med. 1981; 304: 1023-4.
31. Hughes HC Jr, Lang CM. Hepatic necrosis produced by repeated administration of halothane to guinea-pigs. Anesthesiology 1972; 36: 466-71.
32. Lind RC, Gandolfi AJ, Hall P de la M. Covalent binding of oxidative biotransformation intermediates is associated with halothane hepatotoxicity in guinea pigs. Anesthesiology 1990; 73: 1208-13.
33. Lind RC, Gandolfi AJ, Hall P de la M. Glutathione depletion enhances subanesthetic halothane hepatotoxicity in guinea pigs. Anesthesiology 1992; 77: 721-7.
34. Lind RC, Gandolfi AJ, Hall P de la M. Age and gender influence halothane-associated hepatotoxicity in strain 13 guinea pigs. Anesthesiology 1989; 71: 878-84.
35. Murray M, Zaluzny L, Farrell GC. Drug metabolism in cirrhosis. Selective changes in cytochrome P-450 isozymes in the choline-deficient rat model. Biochem. Pharmacol. 1986; 35: 1817-24.
36. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. 1. Evidence for its hemoprotein nature. J. Biol. Chem. 1964; 239: 2370-8.
37. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
38. Peng R, Tennant P, Lorr NA, Yang CS. Alterations of microsomal monooxygenase system and carcinogen metabolism by streptozotocin-induced diabetes in rats. Carcinogenesis 1983; 4: 703-8.
39. Gustafsson J-Å, Ingelman-Sundberg M. Regulation and substrate specificity of a steroid sulfate-specific hydroxylase system in female rat liver microsomes. J. Biol. Chem. 1975; 250: 3451-8.
40. Waxman DJ, Ko A, Walsh C. Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J. Biol. Chem. 1983; 258: 11 937-47.
41. Murray M, Zaluzny L, Farrell GC. Impaired androgen 16α-hydroxylation in hepatic microsomes from carbon tetrachloride-cirrhotic male rats. Gastroenterology 1987; 93: 141-7.
42. Ingelman-Sundberg M, Johansson I, Penttila KE, Glaumann H, Lindros KO, Centrilobular expression of ethanol-inducible cytochrome P-450 (IIEI) in rat liver. Biochem. Biophys. Res. Commun. 1988; 157: 55-60.
43. Tsutsumi M, Lasker JM, Shimizu M, Rosman AS, Lieber CS. The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology 1989; 10: 437-46.
44. Gurll NJ, Reynolds DG, Coon D, Shirazi SS. Acute and chronic splanchnic blood flow responses to portacaval shunt in the normal dog. Gastroenterology 1980; 78: 1432-6.
45. Hursh D, Gelman S, Bradley EL. Hepatic oxygen supply during halothane or isoflurane anesthesia in guinea pigs. Anesthesiology 1987; 67: 701-6.
46. Lind RC, Gandolfi AJ, Hall P De La M. Isoniazid potentiation of a guinea pig model of halothane-associated hepatotoxicity. J. Appl. Toxicol. 1990; 10: 161-5.
47. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacol. Ther. 1990; 45: 1-38.
48. Nebert DW, Nelson DR, Coon MJ et al. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell. Biol. 1991; 10: 1-14.
49. Frost L, Mahoney J, Field J, Farrell GC. Impaired bile flow and disordered hepatic calcium homeostasis are early features of halothane-induced liver injury in guinea pigs. Hepatology 1996; 23: 80-6.